ArticleAdvances in ophthalmology practice and research
GDF11 supplementation improved retinal structure and function in retinal ischemia injury.
Article in Advances in ophthalmology practice and research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Retinal ischemia is a major cause of blindness and plays a detrimental role in various diseases, including occlusion of arteries or veins, diabetic retinopathy, and ocular ischemic syndrome, which could lead to the neuronal and vascular dysfunction. As a result, maintaining their activities may help to avoid visual loss. Growth differentiation factor 11 (GDF11) has been implicated that exert neuroprotective effects and promote the angiogenesis after cerebral or cardiac ischemic injury. Here, we demonstrate that GDF11 has a protective effect on ischemia retinal injury. Methods: To simulate the morphological and functional results following retinal ischemia, a mouse unilateral common carotid artery occlusion (UCCAO) model was employed. Electroretinography (ERG) was conducted to assess the severity of retinal impairment. The effects were evaluated using hematoxylin and eosin (H&E)-staining and immunohistochemistry. In addition, angiogenic activity affected by retinal ischemia was assessed in vivo and in vitro models. Results: We successfully established the UCCAO model and expanded the pathological understanding of UCCAO-induced retinal ischemia. The treatment with GDF11 attenuated cell death, retinal edema, gliosis and apoptosis processes in the acute phase after UCCAO. In addition, GDF11 further reduced apoptosis and improved angiogenesis in the chronic phase after UCCAO. Mechanistically, GDF11 exerted its protective effects by activating the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) pathway, underscoring its potential as a multifaceted therapeutic agent for retinal ischemia. Conclusions: Our study shows the potential of GDF11 as a novel therapeutic for recovering retinal function following retinal ischemia. The results reveal that the therapeutic benefits of GDF11 are exerted during the acute and chronic phases following retinal ischemic injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.